Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

被引：7
|
作者：
Costa, Luciano J. [1 ]
Stadtmauer, Edward A. [2 ]
Morgan, Gareth [3 ]
Monohan, Gregory [4 ]
Kovacsovics, Tibor [5 ]
Burwick, Nicholas [6 ]
Jakubowiak, Andrzej [7 ]
Kaufman, Jonathan L. [8 ]
Mobasher, Mehrdad [9 ]
Freise, Kevin J. [10 ]
Ross, Jeremy A. [10 ]
Pesko, John [10 ]
Munasinghe, Wijith [10 ]
Gudipati, Saketh [10 ]
Mudd, Sarah [10 ]
Bueno, Orlando [10 ]
Kumar, Shaji K. [11 ]
机构：
[1] Univ Alabama, Vestavia, AL USA
[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[3] Univ Arkansas Med Sci, Little Rock, AR 72205 USA
[4] Univ Kentucky, Lexington, KY USA
[5] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA
[6] VA Puget Sound Hlth Care Syst, Seattle, WA USA
[7] Univ Chicago, Chicago, IL 60637 USA
[8] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[9] Genentech Inc, San Francisco, CA USA
[10] AbbVie Inc, N Chicago, IL USA
[11] Mayo Clin, Div Hematol, Rochester, MN USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-117026
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
303
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Costa, Luciano J.
    Davies, Faith E.
    Monohan, Gregory P.
    Kovacsovics, Tibor
    Burwick, Nicholas
    Jakubowiak, Andrzej
    Kaufman, Jonathan L.
    Hong, Wan-Jen
    Dail, Monique
    Salem, Ahmed Hamed
    Yang, Xiaoqing
    Masud, Abdullah A.
    Munasinghe, Wijith
    Ross, Jeremy A.
    Bueno, Orlando F.
    Kumar, Shaji K.
    Stadtmauer, Edward A.
    [J]. BLOOD ADVANCES, 2021, 5 (19) : 3748 - 3759
  • [2] Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
    Costa, Luciano J.
    Stadtmauer, Edward Allen
    Morgan, Gareth John
    Monohan, Gregory P.
    Kovacsovics, Tibor
    Burwick, Nicholas
    Jakubowiak, Andrzej J.
    Mobasher, Mehrdad
    Freise, Kevin
    Ross, Jeremy A.
    Pesko, John Carl
    Munasinghe, Wijith
    Cordero, Jaclyn
    Morris, Lura
    Maciag, Paulo Cesar
    Bueno, Orlando
    Kumar, Shaji
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma
    Boccon-Gibod, Clementine
    Talbot, Alexis
    Le Bras, Fabien
    Frenzel, Laurent
    Royer, Bruno
    Harel, Stephanie
    Lombion, Naelle
    Belhadj, Karim
    Cuccuini, Wendy
    Arnulf, Bertrand
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (03) : E73 - E76
  • [4] Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma
    Chari, Ajai
    Martinez-Lopez, Joaquin
    Mateos, Maria-Victoria
    Blade, Joan
    Benboubker, Lotfi
    Oriol, Albert
    Arnulf, Bertrand
    Rodriguez-Otero, Paula
    Pineiro, Luis
    Jakubowiak, Andrzej
    de Boer, Carla
    Wang, Jianping
    Clemens, Pamela L.
    Ukropec, Jon
    Schecter, Jordan
    Lonial, Sagar
    Moreau, Philippe
    [J]. BLOOD, 2019, 134 (05) : 421 - 431
  • [5] Phase 2, open-label study of venetoclax in combination with carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
    Bueno, Orlando
    Xu, Tu
    Cordero, Jaclyn
    Morris, Lura
    Ross, Jeremy
    Freise, Kevin
    Munasinghe, Wijith
    Leverson, Joel
    Mudd, Sarah
    Verdugo, Maria
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Yong, Kwee
    Mikhael, Joseph
    Risse, Marie-Laure
    Asset, Gaelle
    Martin, Thomas
    [J]. FUTURE ONCOLOGY, 2020, 16 (02) : 4347 - 4358
  • [7] Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma
    Jakubowiak, Andrzej J.
    Jasielec, Jagoda K.
    Rosenbaum, Cara A.
    Cole, Craig E.
    Chari, Ajai
    Mikhael, Joseph
    Nam, Jennifer
    McIver, Amanda
    Severson, Erica
    Stephens, Leonor A.
    Tinari, Kathryn
    Rosebeck, Shaun
    Zimmerman, Todd M.
    Hycner, Tyler
    Turowski, Agata
    Karrison, Theodore
    Zonder, Jeffrey A.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (04) : 549 - 560
  • [8] A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Hans C. Lee
    Jatin J. Shah
    Lei Feng
    Elisabet E. Manasanch
    Rebecca Lu
    Ashley Morphey
    Brandon Crumpton
    Krina K. Patel
    Michael L. Wang
    Raymond Alexanian
    Sheeba K. Thomas
    Donna M. Weber
    Robert Z. Orlowski
    [J]. Blood Cancer Journal, 9
  • [9] A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma
    Lee, Hans C.
    Shah, Jatin J.
    Feng, Lei
    Manasanch, Elisabet E.
    Lu, Rebecca
    Morphey, Ashley
    Crumpton, Brandon
    Patel, Krina K.
    Wang, Michael L.
    Alexanian, Raymond
    Thomas, Sheeba K.
    Weber, Donna M.
    Orlowski, Robert Z.
    [J]. BLOOD CANCER JOURNAL, 2019, 9 (10)
  • [10] First results from the randomized portion of a phase 2 study of venetoclax plus carfilzomib-dexamethasone vs carfilzomib-dexamethasone in patients with t(11;14) relapsed/refractory multiple myeloma
    Kaufman, Jonathan
    Gasparetto, Cristina
    Kovacsovics, Tibor
    Mikala, Gabor
    Masszi, Tamas
    Rosinol, Laura
    Janowski, Wojciech
    Oriol, Albert
    Onishi, Maika
    Liu, Zhuangzhuang
    Badawi, Mohamed
    Ross, Jeremy
    Pothacamury, Rajvineeth
    Bueno, Orlando
    Dobkowska, Edyta
    Stadtmauer, Edward
    Costa, Luciano
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S18 - S18
12345